When the IFNα signature was first recognized in the PBMCs of lupus patients[16], it was observed that the only therapy that extinguished the IFNα signature was high dose intravenous methylprednisolone (IVMP). This evidence concerns the gene IFNA2 and systemic lupus erythematosus.